Loading
Sunday, October 18, 2026 · Vol. I, No. 42Independent · Canadian · Research-first
Before you compare Canadian research sourcesRun the free 10-point COA + batch audit at LynxLabs →
Cagrilintide · research summary
Diabetes, metabolic syndrome and obesity : targets and therapy · 2026. Summary drawn from the study's full text. Each statement is followed by the exact sentence it comes from. This is a research summary, not medical advice.
Systematic review and meta-analysis of randomized controlled trials
“This systematic review and meta-analysis was conducted in accordance with the PRISMA 2020 guidelines.”
Adults with overweight or obesity status and type 2 diabetes
“To evaluate the efficacy and safety of dual-agonist CagriSema vs semaglutide monotherapy, cagrilintide monotherapy, and placebo in adults with overweight/obese status and type 2 diabetes, we searched Embase, MEDLINE, PubMed, and the Cochrane Library up to 14 June 2026 for randomized controlled trials (RCTs).”
6898 participants from 8 randomized controlled trials
“Eight RCTs comprising 6898 participants were included.”
Individual trials ranged from 20 to 68 weeks
“Multi-center RCT (32 wk)”
CagriSema resulted in significantly greater percentage body weight reduction compared to semaglutide, cagrilintide, and placebo
“CagriSema was associated with significantly greater percentage body weight reduction compared to semaglutide [MD −6.60%; 95%CI: −8.51 to −4.68; P<0.0001; I2 =82%], cagrilintide [MD −8.15%; 95%CI: −11.40 to −4.89; P<0.0001; I2 =95%], and placebo [MD −14.30%; 95%CI: −17.41 to −11.19; P<0.0001; I2 =99%].”
CagriSema demonstrated a greater decrease in glycated hemoglobin percentage compared to semaglutide, cagrilintide, and placebo
“A greater decrease in the percentage of glycated hemoglobin was also observed for CagriSema than for semaglutide [MD −0.09%; 95%CI: −0.14 to −0.04; P=0.0004; I2 =39%], cagrilintide [MD −0.87%; 95% CI −1.48 to −0.26; p = 0.005; I2 = 97%], and placebo [MD −1.55%; 95% CI −2.14 to −0.97; p < 0.0001; I2 = 99%].”
CagriSema increased the incidence of any adverse events and gastrointestinal adverse events compared with all comparators
“CagriSema increased any adverse events and gastrointestinal adverse events compared with all comparators.”
Small number of eligible trials, lack of long-term cardiovascular endpoints, and substantial statistical heterogeneity
“Key limitations include the relatively small number of eligible trials and the current lack of long-term cardiovascular endpoints.”
Source: PubMed 42763732 · DOI 10.2147/DMSO.S616418 · all study summaries